Comparable stake leader
Alan H. Auerbach
SEC ownership of PUMA BIOTECHNOLOGY, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001401667.
Disclosed value leader
Alan H. Auerbach
Comparable rows
50/50
Latest evidence
04 Oct 2026
- Public ticker
- PBYI on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Alan H. Auerbach
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Alan H. Auerbach
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
04 Oct 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001401667
- Issuer location
- Los Angeles, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PUMA BIOTECHNOLOGY, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Alan H. Auerbach
Disclosed value leader
Alan H. Auerbach
Comparable rows
50/50
Latest evidence
04 Oct 2026
13D/G
3/4/5
13F
Lead comparable stake: 16%
13D/G row: Alan H. Auerbach
Showing 1-8 of 50 holder rows.
Quick read
Alan H. Auerbach leads the comparable SEC ownership view at 16%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Alan H. Auerbach's linked filing trail.
Comparable ownership
Top 5
Alan H. Auerbach
16%
ACORN BIOVENTURES, L.P.
8%
BlackRock, Inc.
5.6%
MILLENNIUM MANAGEMENT LLC
3.9%
Brian M. Stuglik
0.21%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Alan H. Auerbach |
13D/G
3/4/5
President and CEO, Director, 10%+ Owner
|
16%
|
$85,885,018
8,648,958 shares
|
$0 | 04 Oct 2026 |
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
8%
|
$11,859,557
3,940,052 shares
|
+$1,988,442 | 31 Dec 2024 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$30,856,410
3,804,736 shares
|
— | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
3.9%
|
$5,701,319
1,894,126 shares
|
$0 | 31 Dec 2024 |
| Brian M. Stuglik |
3/4/5
Director
|
0.21%
|
$819,652
113,858 shares
|
-$58,311 | 11 Jun 2026 |
| Allison Dorval |
3/4/5
Director
|
0.17%
|
$653,516
90,780 shares
|
-$83,579 | 11 Jun 2026 |
| Michael Patrick Miller |
3/4/5
Director
|
0.15%
|
$517,590
81,000 shares
|
-$97,228 | 11 Jun 2026 |
| Jay M. Moyes |
3/4/5
Director
|
0.11%
|
$420,968
58,322 shares
|
-$158,796 | 11 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,115,741.
Buys
$0
Insiders: 0
Sells
$2,115,741
Insiders: 10
Net
-$2,115,741
Shares: -283,446
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 283,446
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 67,150 | $0 | $612,494 | -$612,494 |
| 3-6 | 0 | 141,414 | $0 | $1,084,258 | -$1,084,258 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 74,882 | $0 | $418,988 | -$418,988 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to PUMA BIOTECHNOLOGY, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Alan H. Auerbach
Net 12M change
-$2,115,739
Latest report
14 Sep 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Alan H. Auerbach | President and CEO, Director, 10%+ Owner | $60,003,187 | -$568,929 | -0.94% | Filing P/S | 06 Jul 2026 |
| Maximo F. Nougues | Chief Financial Officer | $1,905,753 | -$141,743 | -6.9% | Filing P/S | 06 Jul 2026 |
| Douglas M. Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | $1,626,497 | -$122,600 | -7% | Filing P/S | 06 Jul 2026 |
| Brian M. Stuglik | Director | $819,652 | -$58,311 | -6.6% | Filing P/S | 11 Jun 2026 |
| Allison Dorval | Director | $653,516 | -$83,579 | -11% | Filing P/S | 11 Jun 2026 |
| Alvin F. Wong | Chief Scientific Officer | $633,593 | Mixed | 12 Feb 2024 | ||
| Michael Patrick Miller | Director | $517,590 | -$97,228 | -16% | Mixed | 11 Jun 2026 |
| Alessandra Cesano | Director | $517,274 | -$566,994 | -52% | Filing P/S | 14 Sep 2026 |
| Troy E. Wilson | Director | $502,685 | -$123,248 | -20% | Mixed | 14 Sep 2026 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | $494,161 | Mixed | 07 Feb 2025 | ||
| Jay M. Moyes | Director | $420,968 | -$158,796 | -27% | Filing P/S | 11 Jun 2026 |
| Adrian Senderowicz | Director | $194,310 | -$194,311 | -50% | Filing P/S | 11 Jun 2026 |
| Ann C. Miller | Director | $182,720 | Mixed | 15 Jun 2021 |
Recent insider transactions for PUMA BIOTECHNOLOGY, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Troy E. Wilson | PBYI | Common Stock | Sale | -8.37% | $45,500 | $9.10 | -5,000 | 54,750 | 14 Sep 2026 | Direct |
| Alessandra Cesano | PBYI | Common Stock | Sale | -52.3% | $566,994 | $9.12 | -62,150 | 56,700 | 14 Sep 2026 | Direct |
| Alessandra Cesano | PBYI | Common Stock | Options Exercise | 72.6% | 50,000 | 118,850 | 14 Sep 2026 | Direct | ||
| Alessandra Cesano | PBYI | Stock Option | Options Exercise | -50% | -50,000 | 50,000 | 14 Sep 2026 | Direct | ||
| Alan H. Auerbach | PBYI | Common Stock | Sale | -0.6% | $364,051 | $8.26 | -44,058 | 7,261,671 | 06 Jul 2026 | Direct |
| Douglas M. Hunt | PBYI | Common Stock | Sale | -4.12% | $69,905 | $8.26 | -8,460 | 196,841 | 06 Jul 2026 | Direct |
| Maximo F. Nougues | PBYI | Common Stock | Sale | -3.91% | $77,557 | $8.26 | -9,386 | 230,637 | 06 Jul 2026 | Direct |
| Troy E. Wilson | PBYI | Common Stock | Sale | -15.3% | $77,748 | $7.20 | -10,800 | 59,750 | 12 Jun 2026 | Direct |
| Brian M. Stuglik | PBYI | Common Stock | Sale | -6.64% | $58,311 | $7.20 | -8,100 | 113,858 | 12 Jun 2026 | Direct |
| Adrian Senderowicz | PBYI | Common Stock | Sale | -50% | $194,311 | $7.20 | -27,000 | 27,000 | 12 Jun 2026 | Direct |
| Jay M. Moyes | PBYI | Common Stock | Sale | -27.4% | $158,796 | $7.22 | -22,000 | 58,322 | 12 Jun 2026 | Direct |
| Allison Dorval | PBYI | Common Stock | Sale | -11.3% | $83,579 | $7.20 | -11,610 | 90,780 | 12 Jun 2026 | Direct |
| Troy E. Wilson | PBYI | Common Stock | Award | 62% | 27,000 | 70,550 | 11 Jun 2026 | Direct | ||
| Brian M. Stuglik | PBYI | Common Stock | Award | 28.4% | 27,000 | 121,958 | 11 Jun 2026 | Direct | ||
| Adrian Senderowicz | PBYI | Common Stock | Award | 100% | 27,000 | 54,000 | 11 Jun 2026 | Direct | ||
| Michael Patrick Miller | PBYI | Common Stock | Award | 50% | 27,000 | 81,000 | 11 Jun 2026 | Direct | ||
| Jay M. Moyes | PBYI | Common Stock | Award | 50.6% | 27,000 | 80,322 | 11 Jun 2026 | Direct | ||
| Allison Dorval | PBYI | Common Stock | Award | 35.8% | 27,000 | 102,390 | 11 Jun 2026 | Direct | ||
| Alessandra Cesano | PBYI | Common Stock | Award | 64.5% | 27,000 | 68,850 | 11 Jun 2026 | Direct | ||
| Alan H. Auerbach | PBYI | Common Stock | Award | 2.24% | 159,778 | 7,305,729 | 18 Feb 2026 | Direct | ||
| Alan H. Auerbach | PBYI | Stock Option (Right to Buy) | Award | 227,474 | 227,474 | 18 Feb 2026 | Direct | |||
| Douglas M. Hunt | PBYI | Common Stock | Award | 31.7% | 49,394 | 205,301 | 18 Feb 2026 | Direct | ||
| Douglas M. Hunt | PBYI | Stock Option (Right to Buy) | Award | 70,321 | 70,321 | 18 Feb 2026 | Direct | |||
| Maximo F. Nougues | PBYI | Common Stock | Award | 24.2% | 46,739 | 240,023 | 18 Feb 2026 | Direct | ||
| Maximo F. Nougues | PBYI | Stock Option (Right to Buy) | Award | 66,541 | 66,541 | 18 Feb 2026 | Direct | |||
| Alan H. Auerbach | PBYI | Common Stock | Sale | -0.25% | $105,893 | $5.88 | -18,012 | 7,145,951 | 07 Jan 2026 | Direct |
| Douglas M. Hunt | PBYI | Common Stock | Sale | -3.12% | $29,477 | $5.88 | -5,014 | 155,907 | 07 Jan 2026 | Direct |
| Maximo F. Nougues | PBYI | Common Stock | Sale | -3.21% | $37,655 | $5.88 | -6,405 | 193,284 | 07 Jan 2026 | Direct |
| Alan H. Auerbach | PBYI | Common Stock | Sale | -0.24% | $98,986 | $5.84 | -16,938 | 7,163,963 | 06 Jan 2026 | Direct |
| Douglas M. Hunt | PBYI | Common Stock | Sale | -2.41% | $23,218 | $5.84 | -3,973 | 160,921 | 06 Jan 2026 | Direct |
| Maximo F. Nougues | PBYI | Common Stock | Sale | -2.22% | $26,532 | $5.84 | -4,540 | 199,689 | 06 Jan 2026 | Direct |
| Michael Patrick Miller | PBYI | Common Stock | Sale | -27% | $97,228 | $4.86 | -20,000 | 54,000 | 11 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.